Trial Information
Nexium Capsules Specific Clinical Experience Investigation Concerning Helicobacter Pylori Eradication
Nexium capsules Specific Clinical Experience Investigation concerning Helicobacter pylori
eradication
Inclusion Criteria
Inclusion criteria:
- Triple therapy for H.pylori eradication to stomach started after endoscopic treatment
for gastric ulcer
- Triple therapy for H.pylori eradication to stomach started after endoscopic treatment
for duodenal ulcer
- Triple therapy for H.pylori eradication to stomach started after endoscopic treatment
for gastric MALT lymphoma
- Triple therapy for H.pylori eradication to stomach started after endoscopic treatment
for idiopathic thrombocytopenic purpura
- Triple therapy for H.pylori eradication to stomach started after endoscopic treatment
for early gastric cancer
Exclusion Criteria:
- H.pylori negative at the time when the triple therapy is started
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Number of Adverse Drug Reactions
Outcome Time Frame:
Period from the start of triple therapy to assessment of eradication, an expected average of 3 months
Safety Issue:
Yes
Principal Investigator
Shigeru Yoshida, MD
Investigator Role:
Study Director
Investigator Affiliation:
Astrazeneca K.K.
Authority:
Japan: Ministry of Health, Labor and Welfare
Study ID:
D961HC00011
NCT ID:
NCT01435525
Start Date:
September 2011
Completion Date:
January 2014
Related Keywords:
- Gastric Ulcer
- Duodenal Ulcer
- Gastric Mucosa-associated Lymphoid Tissue (MALT)
- Lymphoma Idiopathic Thrombocytopenic Purpura
- Early Gastric Cancer
- triple therapy
- Helicobacter pylori
- eradication
- Nexium
- Duodenal Ulcer
- Lymphoma
- Stomach Neoplasms
- Purpura
- Purpura, Thrombocytopenic
- Stomach Ulcer
- Ulcer
- Purpura, Thrombocytopenic, Idiopathic